Where Does Lung Cancer Spread?

Common Sites of Lung Cancer Metastases

One of the biggest concerns among people with lung cancer is that the cancer may spread to other parts of the body. This is known as metastasis (plural metastases) and occurs in around 40% of newly diagnosed people. Although this can occur in any part of the body, there are several sites where it is more common.

Sites of lung cancer metastases

Verywell / JR Bee

The article details the five sites where lung cancer most commonly spreads as well as the symptoms it can cause in each location. It also details what can be done to treat it and offers insights into the prognosis (likely outcome) of metastatic lung cancer.

How Does Lung Cancer Spread?

Lung cancer spreads when cancer cells break off from the primary (original) tumor and travel through the bloodstream or lymphatic system. The lymphatic system is a network of vessels and organs that collects, carries, and filters substances from the body, including cancer cells.

Where Does Lung Cancer Spread?

The most common areas for lung cancer to spread are:

Less commonly, lung cancer can spread to the stomach, intestines, pancreas, eyes, skin, kidneys, or breast.

Different stages of the disease indicate how much the cancer has grown and spread. Local spread is known as stage 2. Metastasis occurs when cancer spreads to distant sites. Unlike early-stage cancer that may be cured, metastatic cancer (also known as stage 4 cancer) cannot and is instead managed.

The risk of metastatic lung cancer can also vary by the cancer type. This includes the more common non-small cell lung cancer (NSCLC) and the less common small cell lung cancer (SCLC).

If cancer spreads to other parts of the body, it is still referred to by the site of the primary tumor. For example, if lung cancer spreads to the bone, it is called "lung cancer metastatic to bone" rather than "bone cancer."

Lymph Nodes

Most lung cancers first spread to lymph nodes within the lung or around the major airways. Lymph nodes are tiny organs clustered throughout the body that trap and filter foreign substances.

As long as cancer only spreads to nearby lymph nodes, it isn't considered metastatic. The local spread of cancer to the lymph nodes can occur during stage 2 NSCLC or limited-stage SCLC. People at this stage often have no symptoms.

If left untreated, the cancer can spread to distant lymph nodes and other sites in the body. It is at this stage (called stage 4 NSCLC or extensive-stage SCLC) that you may notice a hardened lump in the neck or armpit where a lymph node has cancer cells.

Surgery is the first-line treatment for early-stage NSCLC and includes the partial or complete removal of nearby lymph nodes. Other treatments such as radiation, chemotherapy, and targeted therapy may be used with surgery or on their own for people with metastatic disease.


The spread of lung cancer to nearby lymph nodes is not considered metastasis. It is only when distant lymph nodes are affected that metastatic lung cancer is diagnosed.


One of the more serious complications of NSCLC is lung cancer metastases to bones. Roughly 30% to 40% of people with advanced lung cancer will develop this.

The areas most affected by bone metastases include:

Pain is the most common symptom. The pain often starts gradually, feeling more like a muscle pull or strain, before turning severe. More severe symptoms may include:

  • Pathologic fractures, which is when the bone breaks in an area weakened by disease
  • Hypercalcemia (high calcium levels in the blood), a condition that can cause symptoms such as confusion, muscle weakness, and loss of appetite
  • Spinal cord compression, if the cancer spreads to the spine

The primary goal of treatment is to reduce pain and prevent fractures. Options include pain medications, radiation, surgery, and drugs used to slow the breakdown of bone.


Bone metastases most often affect the spine, pelvis, thigh bone, upper arm bone, and bones of the hands or feet. Pain and bone fractures are common with advanced disease.


Lung cancer is the most common cancer that spreads to the brain. In fact, as many as 40% of people with lung cancer will develop brain metastases at some point. This can occur with both NSCLC and SCLC but is known to develop rapidly with SCLC.

As many as 44% of people will have no symptoms at all when lung cancer has spread to the brain. Others may experience:

  • Headache, often with nausea or vomiting
  • Confusion
  • Memory loss
  • Seizures
  • Vision loss
  • Numbness or weakness on one side of the body

The treatment is primarily palliative, meaning that the goal is to control symptoms rather than cure the disease. This may involve pain medications, anti-seizure drugs, radiation to shrink tumors, or steroids to decrease brain swelling.

If there are few metastases, surgery or a form of radiation called stereotactic body radiotherapy (SBRT) may be used. For people at risk of brain metastases, another type of radiation called prophylactic cranial irradiation (PCI) may be used to prevent this from occurring.


Lung cancer is the most common cancer that spreads to the brain. While brain metastasis can cause seizures, vision loss, confusion, or weakness on one side of the body, only around four of every 10 people will have symptoms.


Lung cancer that has spread to the liver is common and can affect anywhere from 30% to 50% of people with advanced-stage disease.

Many people with liver metastases will have no symptoms, but those who do may experience:

  • Loss of appetite
  • Weight loss
  • Fatigue
  • Leg swelling
  • Itching
  • Jaundice (yellowing of the skin or eyes)

Chemotherapy is usually recommended to treat both the primary tumor and cancer cells in the liver. This sometimes involves transarterial chemoembolization, a procedure in which a tube called a catheter delivers chemotherapy drugs directly to the liver.

In rare cases, if only a single tumor or a few tumors are found, they may be removed with surgery.

Adrenal Glands

Adrenal glands are organs on the top of the kidneys that produce hormones. Lung cancer that spreads to the adrenal glands does not usually cause symptoms and is most often discovered during the routine staging of cancer.

Treatment with chemotherapy is useful in extending survival. In cases where the lung tumor can be resected (removed), the affected adrenal gland may be removed as well.

How Quickly Does Lung Cancer Spread?

Every cancer is different, so there isn't one answer to this question.

One way to determine how fast any cancer might spread is by examining how long it takes to double in size. The thinking is that the faster it grows, the quicker it may spread. Researchers have found that it takes approximately three to six months for a lung cancer tumor to double in size.

The type of cancer also plays a role in how quickly lung cancer can spread. For example, small cell lung cancer can spread very early regardless of its size, while squamous cell carcinomas of the lung spread when they are larger.

The speed at which lung cancer spreads also depends on whether a tumor has specific mutations that help them spread.

How Is Metastatic Lung Cancer Treated?

Treatment will depend on the patient's individual circumstances, such as age, overall health, and where in the body the cancer has spread. The goal of treatment is to slow or stop the tumor's growth and alleviate symptoms.

Treatment plans typically involve a combination of the following:

  • Immunotherapies to help the body fight off cancer
  • Targeted drug therapy to target abnormalities in tumors
  • Chemotherapy to slow the growth of cancer cells

At this stage, surgery may not be an option if the cancer is too widespread. Patients will typically receive palliative care.

Can Metastatic Lung Cancer Be Cured?

In most cases, metastatic lung cancer is not curable. Some research has shown that certain people with a single metastasis can be cured with surgery, but the cure rate is low and more research is needed.

Other than the spread of cancer to nearby lymph nodes, lung cancer that has metastasized generally has poor outcomes. According to the National Cancer Institute (NCI), the overall five-year survival rate for metastatic lung cancer is 6.3%. This means that around six of every 100 people diagnosed with metastatic lung cancer will live five years or more.

This doesn't mean your chances of survival are necessarily low, however. NCI statistics are based on all people with stage 4 lung cancer, some of whom may be older, less healthy, or have different types of cancer than you. Other issues factor into your individual odds of survival, not least of which is your performance status (a measurement of your ability to perform everyday tasks).

There are also drugs called checkpoint inhibitors, which include Keytruda (pembrolizumab) and Opdivo (nivolumab), that have greatly improved survival times in people with metastatic lung cancer.


The five parts of the body where lung cancer commonly spreads are the lymph nodes, bones, brain, liver, and adrenal glands. The spread may be limited to nearby lymph nodes, where the cancer is more readily treated. If it spreads to distant organs, it is referred to as metastatic lung cancer and is considered incurable.

Even so, there are drugs and treatments that can manage metastatic lung cancer and control symptoms. Although the prognosis of stage 4 lung cancer is generally poor, some people live for many years due to advances in treatment.

22 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288-300. doi:10.21037/tlcr.2016.06.07

  2. Milovanovic IS, Stjepanovic M, Mitrovic D. Distribution patterns of the metastases of the lung carcinoma in relation to histological type of the primary tumor: an autopsy study. Ann Thorac Med. 2017 Jul-Sep;12(3):191–8. doi:10.4103/atm.ATM_276_16

  3. Song SH, Oh YJ, Kim YN, Song HH, Ha CW. Squamous cell carcinoma of the lung with simultaneous metastases to peritoneum and skeletal muscle. Thorac Cancer. 2014;5(1):101-3. doi:10.1111/1759-7714.12034

  4. American Cancer Society. Non-small cell lung cancer stages.

  5. Bao F, Yuan P, Yuan X, Lv X, Wang Z, Hu J. Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer. J Thorac Dis. 2014;6(12):1697-703. doi:10.3978%2Fj.issn.2072-1439.2014.11.05

  6. Shen-Tu Y, Mao F, Pan Y, et al. Lymph node dissection and survival in patients with early stage nonsmall cell lung cancer: A 10-year cohort study. Medicine (Baltimore). 2017;96(43):e8356. doi:10.1097/md.0000000000008356

  7. Roato I. Bone metastases: when and how lung cancer interacts with bone. World J Clin Oncol. 2014;5(2):149-55. doi:10.5306/wjco.v5.i2.149

  8. Ali A, Goffin J, Arnold A, Ellis P. Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastasesCurr Oncol. 2013;20(4):e300-6. doi:10.3747%2Fco.20.1481

  9. Komatsu T, Kunieda E, Oizumi Y, Tamai Y, Akiba T. Clinical characteristics of brain metastases from lung cancer according to histological type: pretreatment evaluation and survival following whole-brain radiotherapy. Mol Clin Oncol. 2013;1(4):692-8. doi:10.3892/mco.2013.130

  10. Schroeder T, Bittrich P, Noebel C, et al. Efficiency of dexamethasone for treatment of vasogenic edema in brain metastasis patients: a radiographic approachFront Oncol. 2019;9:695. doi:10.3389/fonc.2019.00695

  11. Ding LY, Liu KJ, Jiang ZL, Wu HY, Wu SX. Targeted therapy of multiple liver metastases after resected solitary gastric metastasis and primary pulmonary adenocarcinoma. Oncotarget. 2016 Dec 27;7(52):87479–84. doi:10.18632/oncotarget.13114

  12. Ren Y, Dai C, Zheng H, et al. Prognostic effect of liver metastasis in lung cancer patients with distant metastasis. Oncotarget. 2016 Aug 16;7(33):53245–53. doi:10.18632/oncotarget.10644

  13. Wáng YX, De baere T, Idée JM, Ballet S. Transcatheter embolization therapy in liver cancer: an update of clinical evidences. Chin J Cancer Res. 2015;27(2):96-121. doi:10.3978/j.issn.1000-9604.2015.03.03

  14. Oshiro Y, Takeda Y, Hirano S, Ito H, Aruga T. Role of radiotherapy for local control of asymptomatic adrenal metastasis from lung cancer. Am J Clin Oncol. 2011;34(3):249-53. doi:10.1097/coc.0b013e3181dbb727

  15. Bazhenova L, Newton P, Mason J, Bethel K, Nieva J, Kuhn P. Adrenal metastases in lung cancer: clinical implications of a mathematical model. J Thorac Oncol. 2014;9(4):442-6. doi:10.1097/JTO.0000000000000133

  16. Harris K, Khachaturova I, Azab B, et al. Small cell lung cancer doubling time and its effect on clinical presentation: a concise review. Clin Med Insights Oncol. 2012;6:199–203. doi:10.4137/CMO.S9633

  17. Moffitt Cancer Center. How is metastatic lung cancer treated?

  18. City of Hope. Stage 4 lung cancer.

  19. Thippeswamy R, Noronha V, Krishna V, et al. Stage IV lung cancer: Is cure possible? Indian J Med Paed Oncol. 2013;34(02):121-5. doi:10.4103/0971-5851.116207

  20. National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: lung and bronchus cancer.

  21. West HJ, Jin JO. Performance status in patients with cancer. JAMA Oncol. 2015;1(7):998. doi:10.1001/jamaoncol.2015.3113

  22. Chen R, Tao Y, Xu X, et al. The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer. Discov Med. 2018 Oct;26(143):155-66.

By Lynne Eldridge, MD
 Lynne Eldrige, MD, is a lung cancer physician, patient advocate, and award-winning author of "Avoiding Cancer One Day at a Time."